Association Between Tumor Expression of VEGFA, VEGFR1 (FLT1), VEGFR2 (KDR), and Clinical Outcomes in Neuroendocrine Tumors Abstract #823

Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).
Aim(s): We investigated the prognostic significance of expression of VEGF pathway components in NET patients generally, and in a subgroup of patients treated with bevacizumab.
Materials and methods: We evaluated immunohistochemical expression of VEGFA, VEGFR1, and VEGFR2 in a cohort of archival NETs and evaluated associations with overall survival (OS) and progression-free survival (PFS) after adjusting for other clinical prognostic variables.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Zhirong Qian

To read results and conclusion, please login ...

Further abstracts you may be interested in

#912 Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment
Introduction: Everolimus increases PFS in patients with advanced NETs. Currently, no biomarkers are available for early selection of patients who will benefit from everolimus. Everolimus can reduce VEGF-A production by tumor cells.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Adrienne H Brouwers
#993 Analysis of Somatostatin Receptors Expression in Neuroendocrine Tumors
Introduction: Clinical studies have suggested anti-tumor efficacy of somatostatin analog (SSA) in the treatment of neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Tingting Li
Authors: Li T, Qian Z, Ter-Minassian M, Chan J A, ...
Keywords: SSTR2, SSA, NET, OS, PFS
#1094 Experience with Bevacizumab in Neuroendocrine Tumors
Introduction: Bevacizumab has shown promising activity in neuroendocrine tumors (NET) in combination with a multitude of other substances.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. med. Leonidas Apostolidis
#784 Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumors in a Danish NET Center
Introduction: Small intestinal neuroendocrine tumors (NET) have increased in incidence during the past decades. However, time trends from the Nordic countries are sparse.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Henning Grønbæk
Authors: Høj L, Nykjær K M, Grønbæk H, ...
#1309 Dual 18F-Fluorodeoxyglucose/68Gallium DOTATATE (FDG/DOTA) PET Predicts Overall Survival in Neuroendocrine Tumours (NET)
Introduction: 68Ga-DOTATATE (DOTA) and FDG PET have been utilised in NETs to aid diagnosis, prognostication and guide management. FDG PET avidity is associated with poor prognosis, but the prognostic significance of dual FDG/DOTA grading has not been explored.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr David Chan
Authors: Chan D, Bailey D, Schembri G, Bernard E, ...
Keywords: PET, prognosis